Prof Matti Aapro speaks to ecancer on the survival outcomes in randomised controlled trials with first-line CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive, HER2 negative breast cancer (HR+/HER2-Ve BC).

CDK4/6i combined with endocrine therapy are considered standard-of-care for first-line therapy of patients with HR+/HER2- BC. Prof Aapro highlights the concerns of patients who want to have children after endocrine therapy.

Prof Aapro speaks at the BGICC to discuss the survival outcomes of these trials.